Tilray Brands (TLRY) Q1 2027: Record Revenue and Profitability — Cautiously Optimistic

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) reported a record first-quarter net revenue of $257 million, reflecting a $47.6 million or 23% increase year-over-year. This performance underscores the company's robust growth trajectory across its diversified business segments, particularly in international cannabis, beverages, and pharmaceutical distribution.

Key Financial Metrics

• Net Revenue: $257 million, up $47.6 million or 23% YoY
• Gross Profit: $77.5 million, an increase of $20 million or 35% YoY
• Gross Margin: Expanded by approximately 300 basis points to 30%
• International Revenue Growth: EMEA revenue increased by 71%
• Beverage Revenue: $101 million, with a gross margin of 41%
• Adjusted EBITDA Guidance: Reaffirmed at $68 million to $75 million for fiscal 2027

Analyst Opinion

This quarter represents a significant achievement for Tilray, showcasing its ability to drive revenue growth while expanding profitability. The 23% increase in net revenue and the 35% rise in gross profit are particularly noteworthy, indicating effective operational execution and a strong market presence. However, the company reported a net loss of $40.3 million, a stark contrast to the $1.5 million profit from the same quarter last year, which raises concerns about the sustainability of its current growth strategy.

The increase in operational expenses, particularly in general and administrative costs, which rose by 40% to $57.6 million, suggests that while Tilray is investing in growth, it must manage these costs effectively to maintain profitability. The reaffirmation of adjusted EBITDA guidance is a positive sign, but investors should remain cautious given the significant net loss.

Shareholder Returns and Financial Health

Tilray has demonstrated a commitment to strengthening its balance sheet, having reduced outstanding debt by $42 million year-to-date. The company ended the quarter with cash, restricted cash, and marketable securities totaling $221.4 million, providing it with financial flexibility to pursue strategic growth opportunities.

Forward-Looking Catalysts

Investors should closely monitor Tilray's performance in the upcoming quarters, particularly as the company anticipates stronger results in the second half of the fiscal year due to seasonality. The partnership with Carlsberg to produce and sell iconic brands in the U.S. market starting January 1, 2027, could serve as a significant growth driver. Additionally, the ongoing expansion of its international cannabis and beverage segments will be critical to sustaining momentum.

In conclusion, while Tilray's record revenue and gross profit are commendable, the substantial net loss and rising operational costs warrant a cautious approach from shareholders. The company's ability to navigate these challenges while capitalizing on growth opportunities will be pivotal in determining its future performance.

Consolidated Statements of Income (in thousands of US dollars)

Note: The amounts in the following table are in thousands.

Condensed Consolidated Balance Sheets (in thousands of US dollars)

Note: The amounts in the following table are in thousands.

Quarterly Earnings — Revenue vs. Estimate

Revenue vs. Estimate — 5 Quarters

EPS vs. Estimate — 5 Quarters

Analyst Ratings & Price Targets

Wall Street analysts have shown mixed sentiment toward Tilray Brands Inc. (TLRY) in recent updates. Roth Capital upgraded the stock from Neutral to Buy on April 2, 2026, with a $10 price target, suggesting significant upside potential from current levels. Canaccord Genuity initiated coverage with a Hold rating in January 2026, while Alliance Global Partners reiterated its Neutral stance on April 5, 2024, raising its target from $2.25 to $2.75. Earlier, Bernstein initiated coverage in November 2022 with a Market Perform rating and a $3.90 target, while The Benchmark Company downgraded TLRY to Sell in July 2022 with a $3 target. Canaccord had previously upgraded the stock to Buy in March 2022 with a $9 target. The consensus price target implies cautious optimism, though dispersion among analysts reflects ongoing uncertainty about Tilray’s growth trajectory. The latest upgrades signal improving sentiment, but near-term headwinds remain a concern for some.

Technical Analysis — 90-Day Price Chart

Tilray Brands Inc. (TLRY) remains in a bearish trend, with the last price of $3.59 below key moving averages—SMA20 ($3.92), SMA50 ($4.30), and SMA200—confirming sustained downward pressure. The lack of bullish crossovers suggests no near-term reversal signal. RSI(14) at 35.8 is neutral but approaching oversold territory, indicating potential for further downside before exhaustion. Trading volume of 3.2M shares is below the 20-day average of 3.9M, reflecting weak conviction in recent moves. The stock is near the lower end of its 52-week range ($3.38-$5.51), with the proximity to the $3.38 low acting as a critical support level. A breach below may trigger accelerated selling, while resistance is likely near the SMA20 and SMA50 levels. The technical setup suggests continued caution unless volume and momentum improve.